Schedule-dependent anticancer therapy by targeting TNF-alpha to tumor vessels in combination with melphalan and gemcitabine

Authors :: Mortara Lorenzo
Orecchia Paola
Borsi Laura
Castellani Patrizia
Balza Enrica
Carnemolla Barbara
Source :: Frontiers in Immunology. 4
Publication Year :: 2013
Publisher :: Frontiers Media SA, 2013.

Subjects :: Melphalan
Oncology
Schedule
medicine.medical_specialty
business.industry
Internal medicine
Immunology
Immunology and Allergy
Medicine
Tumor necrosis factor alpha
business
Gemcitabine
medicine.drug

Full Text Access

Tools